Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Interest Expenses (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Interest Expenses for 10 consecutive years, with $573000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Interest Expenses changed N/A to $573000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.5 million, a 34.01% increase, with the full-year FY2024 number at $2.5 million, up 8.34% from a year prior.
  • Interest Expenses was $573000.0 for Q3 2025 at Theravance Biopharma, down from $663000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $11.9 million in Q2 2022 to a low of $550000.0 in Q4 2022.
  • A 5-year average of $3.1 million and a median of $644000.0 in 2024 define the central range for Interest Expenses.
  • Peak YoY movement for Interest Expenses: rose 19.43% in 2021, then plummeted 82.0% in 2022.
  • Theravance Biopharma's Interest Expenses stood at $2.1 million in 2021, then tumbled by 74.25% to $550000.0 in 2022, then grew by 10.73% to $609000.0 in 2023, then increased by 5.58% to $643000.0 in 2024, then dropped by 10.89% to $573000.0 in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Interest Expenses are $573000.0 (Q3 2025), $663000.0 (Q2 2025), and $643000.0 (Q1 2025).